In early March, FDA announced its first approval of a biosimilar – Sandoz’ Zarxio. The review of the biosimilar version of Amgen’s Neupogen (filgrastim) took nine months. The approval was not accompanied with an “interchangeable” designation.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
